Shuaihang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuaihang Chen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chenlu Shen
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Jie Hu
School of Public Health, Hebei Medical University, Shijiazhuang, China
1 shared publication - Kaihan Wu
Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Keying Du
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication - Qi-Cong Li
Department of Vascular Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
1 shared publication - Qin Zhang
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39613
Association of circulating visfatin level and metabolic fatty liver disease: An updated meta-analysis and systematic review
Background: The rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD. Methods: We strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis. Results: The results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD = 0.13 [−0.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD = 0.45 [0.05, 0.85]) and in the obese patient subgroup (SMD = 1.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes. Conclusion: The serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin’s potential as a biomarker for MAFLD.
- 13 September 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (37) , e39613
Open AccessAssociation of circulating visfatin level and metabolic fatty liver disease: An updated meta-analysis and systematic review
Background: The rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD. Methods: We strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis. Results: The results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD = 0.13 [−0.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD = 0.45 [0.05, 0.85]) and in the obese patient subgroup (SMD = 1.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes. Conclusion: The serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin’s potential as a biomarker for MAFLD.